Announcements

A Form 4 filed on September 3, 2026 disclosed that Muna Bhanji, a director of Veracyte, Inc. (NASDAQ:VCYT), sold 1,864 shares of common stock on September 1, 2026 pursuant to a pre-established Rule 10b5-1 trading plan.

Director James H. Graves filed a Form 4 with the SEC on September 3, 2026, disclosing two transactions in FirstCash Holdings, Inc. common stock on the same date: a sale of shares and a transfer by bona fide gift to a charitable organization.

Sunil Ratilal Karnawat, Chief Commercial Officer of Rezolute, Inc. (NASDAQ:RZLT), filed a Form 4 on September 3, 2026, reporting the disposition of common shares on September 2, 2026, in connection with the vesting and settlement of Restricted Stock Units.

Paul L. Alpern, VP and General Counsel of Arteris, Inc. (NASDAQ:AIP), filed a Form 4 on September 3, 2026, reporting the exercise of incentive stock options and the sale of 4,000 shares of common stock on September 1, 2026.

Bayview Legacy, LLC filed a Form 4 with the SEC on September 3, 2026, disclosing the sale of 100,000 shares of Arteris, Inc. common stock on September 1, 2026, pursuant to a Rule 10b5-1 trading plan.

A Form 4 filed with the SEC on September 3, 2026 discloses that K. Charles Janac, President and CEO of Arteris, Inc. (NASDAQ:AIP), disposed of 100,000 shares of common stock on September 1, 2026 through a pre-established 10b5-1 trading plan.

Simrat Randhawa, EVP and Head of R&D at Dianthus Therapeutics, Inc. (NASDAQ:DNTH), filed a Form 4 on September 3, 2026, disclosing option exercises and common stock sales executed on September 1, 2026, pursuant to a Rule 10b5-1 trading plan.